Cannabis Law Report

AUGUST 27, 2021

This impressive group represents well-known leaders in the psychedelic and addiction fields and will help usher in a greater understanding of the science and data behind what we expect to be the most effective treatments for many mental health conditions ever available.”. Chris Ray , PhD : Interventional Pain Physician.

Research and Development 98

Research and Development Treatment Media Medicine 98

Cannabis Law Report

AUGUST 16, 2021

It is also a tool used to “determine the nature and scope of child abuse and neglect” and compare Arizona data to national trends, regardless of whether that neglect or abuse arose from the lawful or unlawful use of substances, a mental illness or incapacity, or simply an inability to properly care for a child. Share Donate now.

Safety 116

Safety Patients Cannabis Law 116

Cannabis Law Report

JANUARY 23, 2022

I did not know what to expect and as well as presenting my first scientific poster, I was gaining my first taste of the academic world. But a few presentations from the week of presentations stood out to me. Events like these afford us a glimpse into the future of research and medicine in this field. Implications.

Research and Development 52

Research and Development Wellness and Beauty Patients CBD 52

Cannabis Law Report

JUNE 12, 2021

The Parker Psychedelic Research Chair is being funded by Calgary businessman Jim Parker, who donated $3 million to the Hotchkiss Brain Institute to establish the program. “The data was showing that psychedelics were providing benefits to people suffering from anxiety, depression, addiction and PTSD.

Therapy 105

Therapy Treatment Medicine Sleep 105

Cannabis Law Report

APRIL 8, 2022

MAPS continued to publish Bulletin articles about MDMA research , requests for donations , and discontinuing animal studies. MAPS started research into ayahuasca for addiction , and the late Ashawna Hailey provided a donation of $5.5 presented the first official TED Talk about psychedelics. MAPS Founder Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

NORML

SEPTEMBER 20, 2019

And you can imagine how that would harm your efficacy data, because suddenly the patient may need to smoke two bowls just to get any therapeutic benefit, and by then they’ve developed so much bronchial irritation that they often can’t reach that therapeutic threshold. It’s not reflective of real-world cannabis.

DEA 230

DEA Research and Development Clinical Trials Patients 230